000			04327cam a2200625 i 4500
001			ocn899279901
003			OCoLC
005			20221128212825.0
006			m d
007			cr |||||||||||
008			140923s2015 nyu ob 001 0 eng
010			_a 2020687203
040			_aDLC _beng _erda _cDLC _dN$T _dE7B _dOCLCF _dEBLCP _dD6H _dYDX _dSTF _dSCB _dYDXCP
019			_a914151426 _a923677268 _a928196480
020			_a9781634632461 _qebook
020			_a163463246X
020			_z9781634632270
020			_z1634632273
035			_a940572 _b(N$T)
035			_a(OCoLC)899279901 _z(OCoLC)914151426 _z(OCoLC)923677268 _z(OCoLC)928196480
060		4	_aWH 170
072		7	_aHEA _x039000 _2bisacsh
072		7	_aMED _x014000 _2bisacsh
072		7	_aMED _x022000 _2bisacsh
072		7	_aMED _x112000 _2bisacsh
072		7	_aMED _x045000 _2bisacsh
049			_aMAIN
245	0	0	_aHemolytic uremic syndrome : _bsymptoms, treatment options, and prognosis _c _h[E-Book]
264		1	_aNew York : _bNova Biomedical, _c[2015]
300			_a1 online resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
490	1		_aRenal and urologic disorders
504			_aIncludes bibliographical references and index.
588			_aDescription based on print version record.
505	0		_aChapter I: The Role of Thrombin in Hemolytic Uremic Syndrome and Other Thrombotic Microangiopathies; Abstract; Introduction; 1. Thrombin Activation in EndothelialCell Physiology; 2. Modulation of Thrombin in TMAs; 3. Effects of Shiga Toxin on EndothelialCells and Thrombin Production; 4. Animal Models; 5. Treatments Targeting Thrombin in HUSand TMAs.
505	8		_a6. Inflammation and Thrombosis:Connections and ConvergenceConclusion; References -- Chapter II: Therapeutic Apheresis in Children with Renal Diseases, Especially Hemolytic Uremic Syndrome; Abstract; Introduction; Hemolytic-Uremic Syndrome (HUS); Rapidly Progressive Glomerulonephritis (RPGN); Anti-Basement Membrane Antibody Glomerulonephritis (Goodpasture Syndrome, ABM-ab-GN); Immune Complex Nephritis (ICN); RPGN with or without Glomerular Deposition (ANCA ab) Pauci-Immune RPGN; Therapy Recommendations for RPGN; Glomerulonephritis with Nephrotic Syndrome (NS); Myoglobulinemic Renal Failure.
505	8		_aAcute Kidney Injury (AKI)Kidney Transplant Rejection; Summary; References -- Chapter III: The Consequences of Soliris�Therapy in Patients with aHUS; Abstract; Background; The Role of Complement in aHUS; Limitations of Supportive Care Options; Eculizumab; Treatment; Ethical Annotation; Conclusion; References -- Chapter IV: Hemolytic Uremic Syndrome: Overview and Update; Abstract; HUS is Classified Accordingto the Etiology into 3 Categories; Epidemiology; Symptoms; Extrarenal Complications; Pathogenesis; Diagnosis; Treatment Options; Prognosis; Conclusion; References; Blank Page; Index.
520			_aHemolytic uremic syndrome (HUS) is characterized by the triad non-immune micro-angiopathic hemolytic anemia, thrombocytopenia and acute renal failure. The disease mainly affects children one to ten years of age. It begins after an incubation period of 4 to 7 days with abrupt onset of bloody diarrhea and abdominal pain. Two to ten days later, microangiopathy, haemolytic anaemia, thrombocytopenia, and acute renal failure develop. HUS microangiopathy can involve almost any organ, but damage to kidneys and central nervous system cause the most severe clinical problems. This book discusses the symp.
590			_aMaster record variable field(s) change: 050, 082
650		0	_aHemolytic-uremic syndrome.
650		0	_aKidneys _xDiseases.
650	1	2	_aHemolytic-Uremic Syndrome.
650	2	2	_aKidney Diseases.
700	1		_aClayton, Glenna, _eeditor.
830		0	_aRenal and urologic disorders.
856	4	0	_uhttps://search.ebscohost.com/login.aspx?custid=ns123844&authtype=ip,shib&direct=true&scope=site&db=nlebk&db=nlabk&AN=940572 _yKingston Hospital NHS Foundation Trust OpenAthens account holders click here for access
938			_aYBP Library Services _bYANK _n12092714
938			_aEBSCOhost _bEBSC _n940572
938			_aebrary _bEBRY _nebr10997880
938			_aProQuest Ebook Central _bEBLB _nEBL2084866
942			_n0
994			_a92 _bN$T
999			_c92089 _d92089